Clinical trial finds novel therapy markedly reduces lipoprotein(a) levels in people with cardiovascular disease

Lipoprotein(a) is a special type of bad cholesterol that is believed to contribute to heart disease, but there are no approved pharmacological therapies to decrease its concentration in the bloodstream. Olpasiran is an investigational drug that reduces lipoprotein(a) concentration by degrading the RNA that codes for a protein that is an essential part of the molecule.

source https://medicalxpress.com/news/2022-11-clinical-trial-therapy-markedly-lipoproteina.html